Compare ARLO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | EYPT |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2018 | 2005 |
| Metric | ARLO | EYPT |
|---|---|---|
| Price | $13.49 | $12.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $24.00 | ★ $31.80 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-29-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $8.88 | N/A |
| Revenue Next Year | $9.23 | $965.51 |
| P/E Ratio | $96.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $3.91 |
| 52 Week High | $19.94 | $19.11 |
| Indicator | ARLO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 35.42 |
| Support Level | $13.09 | $11.88 |
| Resistance Level | $14.34 | $14.24 |
| Average True Range (ATR) | 0.72 | 1.16 |
| MACD | 0.02 | -0.43 |
| Stochastic Oscillator | 41.39 | 0.17 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.